2017 Genitourinary Cancers Symposium

The addition of cisplatin to standard therapy with gemcitabine and nab-paclitaxel was associated with a median overall survival that “has not been seen in stage IV pancreatic cancer,” according to Gayle Jameson, MSN, ACNP-BC, Nurse Practitioner Investigator of Clinical Trials, HonorHealth Research Institute, Scottsdale, AZ.
Adding vemurafenib to cetuximab and irinotecan prolonged progression-free survival (PFS) and improved the disease control rate in patients with BRAF V600E mutation–positive colorectal cancer (CRC).
Despite consultations with oncologists about the goal of treatment, more than one-third of men with incurable prostate cancer believed that a cure was possible with the treatments they were about to receive.

Results 1 - 7 of 7

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code